Ascentage Pharma to Showcase Preclinical Data for Three Drug Candidates at AACR 2026
Event summary
- Ascentage Pharma will present four preclinical study abstracts at the AACR Annual Meeting 2026, held April 17-22 in San Diego.
- The data covers three drug candidates: Olverembatinib (HQP1351), APG-2449, and APG-5918.
- Olverembatinib is already approved in China for CML treatment and is in global Phase III trials.
- Lisaftoclax, another key product, is approved in China for CLL/SLL and in multiple global Phase III trials.
The big picture
Ascentage Pharma's presentation at AACR 2026 underscores its focus on innovative cancer therapies, particularly in targeting unmet medical needs. The company's partnerships with leading biotech and pharmaceutical firms, along with its robust pipeline, position it as a key player in the global oncology market. The strategic emphasis on both preclinical and clinical advancements highlights its dual approach to drug development and commercialization.
What we're watching
- Clinical Progress
- Whether Olverembatinib's global Phase III trials will yield positive results, potentially expanding its approval beyond China.
- Pipeline Development
- The pace at which APG-2449 and APG-5918 advance from preclinical to clinical stages.
- Regulatory Strategy
- How Ascentage Pharma navigates regulatory pathways in the U.S. and EU for its key drug candidates.